A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
Price : $35 *
At a glance
- Drugs IFX 1 (Primary)
- Indications Sepsis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms SCIENS
- Sponsors InflaRx
- 22 Apr 2016 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Top-line results published in an InflaRx media release.
- 19 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTerials.gov record.